Targeting the Hsp90 C-terminal domain by the chemically accessible dihydropyrimidinone scaffold1. Issue 18 (4th March 2015) - Strocchia, Maria
Abstract Identification of a first DHPM-based lead compound useful for developing a new class of Hsp90 C-terminal inhibitors for cancer therapy.